T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Franklin Resources is a global investment management organization known as Franklin Templeton Investments. They have an extensive global presence, including offices in 35 countries and clients in more than 150. Their common stock is listed on the New York Stock Exchange under the ticker symbol BEN and is included in the Standard & Poor’s 500:registered: Index. Franklin Resources Inc. NYSE: BEN is an investment firm originally founded in New York in 1947 as Franklin Distributors, Inc. It is listed on the NYSE under the ticker BEN as in Benjamin Franklin, whom founder Rupert Johnson, Sr. admired. In 1973 the headquarters moved from New York to San Mateo, California. The firm specializes in conservatively managed mutual funds. It offers products under the Franklin, Templeton, Mutual Series and Fiduciary brand names. Like other large investment companies, the firm offers a wide variety of funds but is traditionally best known for bond funds under the Franklin brand, international funds under the Templeton brand, and value funds under the Mutual Series brand.

Franklin Templeton

Fidelity is a privately-owned investment manager focusing on a diverse set of customers. It also provides IRAs, 401(k) rollovers, annuities, discount brokerage services, retirement services, estate planning, wealth management, securities execution and clearance, and life insurance services to its clients. Fidelity provides its services to individual investors, businesses, financial advisors, and institutions. It manages equity, fixed income, and balanced mutual funds. Fidelity invests in the public equity and fixed income markets across the globe. It conducts in-house research to make its investments.  It helps over 32 million people feel more confident in their most important financial goals, manage employee benefit programs for over 22,000 businesses, and support more than 13,000 financial institutions with innovative investment and technology solutions to grow their businesses. Headquartered in Boston, Fidelity serves its customers through 12 regional offices and more than 190 Investor Centers in the United States.

Fidelity

Deerfield Capital Management (''DCM'') is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.

Deerfield Capital Management

Jennison Associates has earned a reputation for excellence by fulfilling client investment needs since its founding in 1969. Today, the firm manages  over $93 billion for institutions and private clients through separately managed accounts and commingled vehicles, including mutual funds through subadvisory relationships.

Jennison Associates

Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Perceptive Advisors

Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.

Surveyor Capital

venBio Select Advisor LLC is an investment manager for venBio

venBio Select Advisor

Sustainable Private Equity and Credit Investments

Cowen Investment Management

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Pfizer

TPG is a private investment firm that manages capital across a family of funds. TPG Capital is a private equity firm. The firm specializes in providing growth capital to firms in the consumer, healthcare, business services, internet, digital media & communications, software, and enterprise technology sectors. The company also makes real estate investments.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases. Gilead's primary areas of focus include HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions.

Gilead Sciences

Bellco Capital is a private equity firm based in Los Angeles, California.

Bellco Capital

We work with experienced teams to build outstanding companies that improve health outcomes and quality of life. At Two River we tailor our approach to the needs of each opportunity, partnering with management to create, finance or operate development-stage companies in the life sciences and healthcare sectors.  Two River invests in companies with strong intellectual property and proven leadership teams who have demonstrated prior success developing innovative technologies in the life sciences sector.  Two River is uniquely positioned to understand and balance the needs of the finance and life science communities. Our experience building companies spans a range of industry sectors including oncology, cardiovascular disease, ophthalmology, neurological disorders and animal health. We consider each of our investments to be a partnership, often working closely with portfolio companies on product development, regulatory and corporate strategy as well as day-to-day business operations.

Two River

Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists, physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine  .

Vida Ventures

Allogene Therapeutics

Antion Biosciences SA (Antion) is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies to treat and cure diseases with significant unmet medical needs. Our proprietary technologies allow for the creation of multimodal treatments that aim to substantially enhance clinical safety and efficacy. We have a number of products in preclinical development, and it is our mission to translate our proprietary technologies into meaningful therapies for the benefit of patients. We are fully committed to creating high-value therapeutic assets, while developing strategies to ensure broad accessibility of our treatments, especially to resource poor communities. Our patent-protected technologies are versatile, highly effective and broadly applicable to various therapeutic areas. We believe that these technologies will allow us to create both first-in-class and best-in-class therapies. We recognize that strengthening our IP portfolio is central to the commercial success of Antion, and strive to enhance and protect our core technologies further. We actively explore collaborations and partnering opportunities to out-license our proprietary technologies and in-license novel technologies that are commercially important to us. Antion is founded by a team of leading researchers, entrepreneurs and financial executives. Our founders and researchers are recognized scientists and clinicians from the Universities of Geneva, Zurich and Pretoria, with proven track records in molecular medicine and gene engineering. The team has a long collaborative history and previous success in establishing other biotech ventures. Antion’s executive team has broad experience in financial administration, trading, fundraising, initial public offerings, and mergers and acquisitions

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

<div>
  <p>
    Allogene Therapeutics is a biotechnology company that develops allogeneic chimeric antigen receptor T cell therapies for cancer treatments. Allogeneic cell products have the potential to treat over 100 patients from a single manufacturing run, provide off-the-shelf for on-demand treatment, offer multiplex gene engineering and editing capabilities, facilitate scalable and efficient manufacturing, and present product optimization opportunities. The company&rsquo;s pipeline of programs includes ALLO-501A, ALLO-501, ALLO-715, ALLO-605, ALLO-316 and ALLO-819. Moreover, it conducts clinical trials on some of its products to obtain regulatory approval for new medications. Allogene Therapeutics is a publicly held company with offices in three locations.
  </p>
  <p>
  </p>
</div>


Allogene Therapeutics

Company Brief

Funding

Investors

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless